Overview

The Brown University/Lifespan Hematology/Oncology group was formed when The Miriam Hospital Hematology/Oncology Division, the Rhode Island Hospital Division of Hematology and the Rhode Island Hospital Department of Medical Oncology merged in 1999. Our mission is to achieve academic excellence in basic research, clinical research and education, and to provide the highest quality of care to our patients.

The creation of a Comprehensive Cancer Center, which is a collaborative effort to provide coordinated and comprehensive care for cancer patients at three Lifespan hospitals (The Miriam Hospital, Rhode Island Hospital and Newport Hospital), has now become a reality. Both the patients and the staff appreciate the many benefits afforded by the new Comprehensive Cancer Center at The Miriam Hospital which opened in May 2002. Extensive renovations to the George Clinic at Rhode Island Hospital were completed as a temporary measure. The groundbreaking ceremony for the Comprehensive Cancer Center at Rhode Island Hospital was held on April 28, 2003 with an anticipated opening in February 2004.

A recent goal has been the establishment of multidisciplinary clinics for all the major malignancies. This conveniently allows the patient to receive the expertise of the surgeon, radiation oncologist and medical oncologist at the time of their first visit. Presently, upper GI and melanoma multidisciplinary clinics are up and running at Rhode Island Hospital. A thoracic multidisciplinary tumor board has been implemented at each hospital. Future multi-disciplinary clinics are being planned for head and neck cancer as well as breast cancer.

In the clinical arena, three of our physicians, Drs. Fred Schiffman, Anthony Mega, and Sundaresan Sambandam were included in the “Rhode Island Monthly” magazine’s list of “Top Docs.” Dr. Mega was also honored with the “Teacher of the Year 2001-2002” award by the Hematology/Oncology fellows.

Our laboratory and clinical researchers distinguished themselves through national appointments as well as being awarded significant research grants. A Center of Biomedical Research Excellence (COBRE) award of $8.2 million has established the Center for Cancer Research Development under the leadership of Dr. Douglas Hixson as Principal Investigator and Dr. Nancy Thompson as Deputy Director. The mission of the Center is to foster outstanding interactive, laboratory-based cancer...
research focused on the Molecular and Cellular Pathogenesis of Cancer by mentoring promising junior investigators and establishing state of the art core facilities.

Dr. Douglas Hixson served as a member of the National Institute of Environmental Health Services (NIEHS) Study Section, Review of ToxicoGenomics Consortium Member Applications, 2001 and was the Chair and organizer of the 12th International CEA Symposium in Providence, RI. Dr. Hixson is on the Editorial Board for “Hepatology,” a member of the Program Committee for the American Society for Investigational Pathology and is Vice President and co-founder of ProThera Biologics in East Providence, RI. He received an RO1 grant funded by the National Institutes of Health for a project entitled “Genesis of Liver Carcinomas with Oval Cell Traits.”

Dr. Nancy Thompson is the Principal Investigator for a National Institutes of Health (NIH) RO1 Grant entitled “Expression and Role of TA1 Oncofetal Gene in Liver Cancer” and an American Institute for Cancer Research (AICR) Grant entitled “Amino Acid Regulated Gene Expression in Tumorigenesis.”

Dr. Alan Rosmarin chairs the American Cancer Society’s Leukemia, Immunology and Blood Cell Development Study Section and is a member of the National Cancer Institute Subcommittee C (Program Projects).

Dr. Deborah Britt is the Principal Investigator for two grants that were awarded – a Lifespan Developmental Grant entitled “Examination of Differential Expression of a Novel Protein, LYRIC, in Normal Rat Liver and Hepatocellular Carcinoma” and a grant from the U.S. Army Prostate Cancer Research Program entitled “Examination of a Novel Protein, LYRIC, and Its Involvement in Prostate Tumor Suppression Mediated by the Cell Adhesion Molecule CEACAM1-L.”

Dr. Yow-Pin Lim was awarded a Lifespan Developmental Grant for a project entitled “Granzyme in Sepsis,” which will examine the role of lymphocyte serine proteases (granzymes) in inflammation and sepsis. He also received grants from The Slater Center for Biological Research and NIH/NIGMS (SBIR Phase I). Dr. Lim is the President and co-founder of ProThera Biologics, a start-up biotechnology company, in East Providence, Rhode Island. Dr. Loren Fast was awarded a Rhode Island Cancer Council Grant.

Dr. Howard Safran is the Principal Investigator for an RTOG-sponsored adjuvant pancreatic cancer trial, which is the largest adjuvant pancreatic trial ever performed in the United States. He also directs a Radiation Therapy Oncology Group (RTOG) trial

Alan Rosmarin,
Associate Professor
of Hematology-Oncology; Interim
Director of
Hematology
Division at Brown
Medical School and
Director of Brown
University
Oncology Group
(BrUOG)
for advanced pancreatic cancer. Dr. William Sikov served as a Principal Investigator for a national study in advanced breast cancer, which he presented at the American Society of Clinical Oncology (ASCO) meeting in May 2002. He also serves as a member of the Board of Directors of Cancer and Leukemia Group B (CALGB) and as the Principal Investigator representing Rhode Island. Dr. Anita Kestin is the Principal Investigator for the Prevention of Recurrent Venous Thromboembolism (PREVENT) study. The PREVENT trial evaluates the efficacy of prolonged treatment with low-dose warfarin in the secondary prevention of venous thromboembolism.

Dr. Gary Strauss was recently recruited to fill a fulltime faculty position in Hematology/Oncology at Rhode Island Hospital. Dr. Strauss received his M.D. from Yale University and M.P.H. from Harvard School of Public Health. While he is an experienced clinician in all aspects of Medical Oncology, he is particularly interested in breast and lung cancers. He is a nationally recognized researcher in lung cancer and has been in the forefront of the controversy regarding the efficacy of lung cancer screening. Dr. Strauss’s clinical expertise and research accomplishments make him an invaluable addition to the Division of Hematology/Oncology.

We are proud to report that five of our fellows were authors of abstracts at the American Society of Clinical Oncology (ASCO) meeting in May 2002. One of the fellows, Dr. Vanessa Johnson, received both a Merit Award and the Pain Merit Award, which was presented to the author who submitted the best abstract paper on the subject of pain management. Dr. Johnson was honored during the Opening Ceremony and was also featured in the ASCO daily newsletter.

The Cancer Program at Rhode Island Hospital as well as the Cancer Program at The Miriam Hospital were surveyed by the Commission on Cancer of the American College of Surgeons and both were awarded the maximum accreditation of three years.

Three members of The Miriam Hospital Cancer Control Committee who are actively involved in community activities are Marsha Weiss, RN, MS, Patricia Grossi, RN, BSN, OCN, and Kathleen Higginbotham, LICSW. Ms. Weiss is the Director of Lifespan Community Health Services, which coordinates community health education, screenings, outreach programs and follow-up for the Lifespan affiliates in Rhode Island. She also serves as the local Chair for the National Cancer Survivors Day planning group. Ms. Grossi is an Oncology Nurse Clinician at The Miriam Hospital and serves on the Board of Directors of The Leukemia and Lymphoma Society. Ms. Higginbotham, who is an Oncology Clinical Social Worker at The Miriam Hospital, also volunteers for The Leukemia and Lymphoma Society. Both Ms. Grossi and Ms. Higginbotham coordinate and participate in numerous activities such as National Cancer Survivors Day as well as various support and educational programs, some of which are held in conjunction with the American Cancer Society. They also have been invited to address PTA meetings about speaking to children about cancer and they have conducted tours of the treatment area for young children of cancer patients. Recently Pat Grossi has taken a job at another institution and we are in the process of hiring an equally accomplished and experienced oncology nurse to fill her position.

Faculty Members

**FULL-TIME FACULTY**
(Hospital and Foundation Based)

Edward Wittels, M.D., Director, Hematology/Oncology, Associate Professor, Miriam Hospital, University Medicine Foundation
Deborah Britt, Ph.D., Assistant Professor, Oncology, Rhode Island Hospital
James Butera, M.D., Clinical Assistant Professor, Hematology, Rhode Island Hospital, University Medicine Foundation
James Crowley, M.D., Professor, Hematology, Memorial Hospital
Loren Fast, Ph.D., Associate Professor, Hematology, Rhode Island Hospital
Mary Anne Fenton, M.D., Clinical Instructor, Hematology, Rhode Island Hospital, University Medicine Foundation
Michelle Haskell, Ph.D., Assistant Professor (Res.), Rhode Island Hospital
Douglas Hixson, Ph.D., Professor, Oncology, Rhode Island Hospital
Vanessa Johnson, M.D., Instructor (Research) Miriam Hospital
Anita Kestin, M.D., Clinical Assistant Professor, Hematology, Rhode Island Hospital, University Medicine Foundation
Yow Pin Lim, M.D., Ph.D., Assistant Professor, Oncology, Rhode Island Hospital
Leslie Lockridge, M.D., Assistant Professor, Memorial Hospital
Anthony Mega, M.D., Assistant Professor, Hematology, Miriam Hospital, University Medicine Foundation
Ahmed Nadeem, M.D., Assistant Professor, Memorial Hospital
Neal Ready, M.D., Assistant Professor, Oncology, Rhode Island Hospital, University Medicine Foundation
Alan Rosmarin, M.D., Associate Professor, Hematology/Oncology, Miriam Hospital, University Medicine Foundation
Howard Safran, M.D., Assistant Professor, Oncology, Miriam Hospital, University Medicine Foundation
Fred Schiffman, M.D., Professor, Hematology, Miriam Hospital, University Medicine Foundation
William Sikov, M.D., Clinical Assistant Professor, Oncology, Miriam Hospital, University Medicine Foundation
Gary Strauss, M.D., M.P.H., Brown faculty appointment pending, Rhode Island Hospital, University Medicine Foundation
Rochelle Strenger, M.D., Clinical Assistant Professor, Hematology, Miriam Hospital, University Medicine Foundation
Nancy Thompson, Ph.D., Professor, Oncology, Rhode Island Hospital

VOLUNTEER FACULTY

Kwang Ahn, M.D., Clinical Assistant Professor, Oncology, Roger Williams Medical Center
Joseph DiBenedetto, Jr., M.D., Clinical Assistant Professor, Hematology/Oncology, Rhode Island Hospital

Nancy Freeman, M.D., Clinical Associate Professor, Hematology, VA Medical Center
Linda Hassan, M.D., Clinical Assistant Professor, Memorial Hospital
Peter Hoffmann, M.D., Clinical Assistant Professor, Hematology, Miriam Hospital
Plakyil Joseph, M.D., Clinical Assistant Professor, Oncology, Roger Williams Medical Center
A. Sattar Memon, M.D., Clinical Associate Professor, Oncology, Memorial Hospital
Vishram Rege, M.D., Clinical Associate Professor, Oncology, Rhode Island Hospital
Peter Rintels, M.D., Clinical Assistant Professor, Oncology, Rhode Island Hospital
Sundaesan Sambandam, M.D., Clinical Assistant Professor, Oncology, Rhode Island Hospital
Anthony Testa, M.D., Clinical Instructor, Oncology, St. Joseph’s Hospital
Kathy Theall, M.D., Clinical Instructor, Hematology/Oncology, Memorial Hospital
Anthony Thomas, D.O., Clinical Assistant Professor, Hematology, Rhode Island Hospital
Fred Vohr, M.D., Clinical Assistant Professor, Hematology/Oncology, Rhode Island Hospital
Francis Cummings, M.D., Adjunct Associate Professor, Oncology, Roger Williams Medical Center
A. Raymond Frackelton, Ph.D., Adjunct Associate Professor, Oncology, Roger Williams Medical Center
Seth Rudnick, M.D., Adjunct Associate Professor, Oncology, Rhode Island Hospital
Philip Schein, M.D., Adjunct Professor, Oncology, Rhode Island Hospital
Alan Weitberg, M.D., Adjunct Professor, Oncology, Roger Williams Medical Center

FACULTY TRANSITIONS

<table>
<thead>
<tr>
<th>Departing Faculty</th>
<th>New Faculty</th>
</tr>
</thead>
</table>
| Thomas Myers, Clinical Associate Professor, Memorial Hospital | James Butera, M.D., Clinical Assistant Professor, Rhode Island Hospital
| Peter Hoffmann, Clinical Assistant Professor, Miriam Hospital | Gary Strauss, M.D., MPH, Appointment pending, Rhode Island Hospital

<table>
<thead>
<tr>
<th>Name</th>
<th>Former Position</th>
<th>Faculty Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Butera, M.D., Clinical Assistant Professor, Rhode Island Hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gary Strauss, M.D., MPH, Appointment pending, Rhode Island Hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leslie Lockridge, M.D., Assistant Professor, Memorial Hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ahmed Nadeem, M.D., Assistant Professor, Memorial Hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vanessa Johnson, M.D., Instructor (Research) Miriam Hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michelle Haskell, Ph.D., Assistant Professor (Res.) Rhode Island Hospital</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
National and International Honors and Recognition of Faculty

Loren Fast, PhD
Invited presentations:
• Two seminars at the Blood Center of the Pacific, San Francisco, CA

Mary Anne Fenton, M.D.
Invited presentation:
• "Pathophysiology of Breast, Cervical and Endometrial Cancers" at University of Rhode Island, Kingston, RI

Douglas Hixson, PhD
• Chair and organizer, 12th International CEA/PSG Symposium, Providence, RI; Consultant, Octapharma Therapeutics, Vienna, Austria
• Member, Editorial Board of "Hepatology"
• Member, Program Committee for American Society for Investigational Pathology
• Vice President, co-founder of Prothera Biologics, East Providence, RI

Invited presentations:
• "Hepatic Stem Cells, An Older and Wiser Alternative to Embryonic Stem Cells" at UTMDAH Cancer Center, Science Park Research Division, Smithville, TX
• "Stages in Hepatic Ductal Cell Development Defined by Surface Reactive Monoclonal Antibodies" at Albert Einstein College of Medicine, Bronx, NY "Hepatic Stem Cells of Ductal Origin" at Loyola University, New Orleans, LA

Anita Kestin, M.D.
Invited presentations:
• "Coagulation Disorders" at University of Rhode Island, Kingston, RI
• "Hematology Update: Hypercoagulable States" at Newport Hospital’s Grand Rounds, Newport, RI

Yow Pin Lim, M.D., PhD
Invited presentations:
• "Development of Monoclonal Antibody for Early Detection of Colon Cancer" at Biochemistry Seminar at the Free University, Berlin, Germany
• "Inter-alpha inhibitors in Sepsis and Cancer" at Institute for Immunology Zagreb and Dr. Josip Hospital, Zagreb, Croatia
• "Role of Protease Inhibitors in Neonatal Sepsis" at 28th Annual New England Conference on Perinatal Research, Chatham, MA

Anthony, Mega, M.D.
• "TopDoc" – Rhode Island Monthly Magazine

Invited presentations:
• "Communicating Options in Prostate Cancer" at Schwartz Center Rounds, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island
• "High Risk Local Prostate Cancer – Can We Improve Outcome?" at Brown University Oncology Group Education Advisory Board, Edgartown, MA
• "From Herbs to Chemotherapy, Choices in the Management of the Patient with Androgen-Independent Prostate Cancer" at Caritas Good Samaritan Medical Center, Brockton, MA
• "Update on Prostate Cancer" at CRI Communications on The Rhode Island Health Update program, Providence, RI

Neal Ready, M.D., PhD
Invited presentation:
• Abstract/poster "Induction Weekly Paclitaxel and Carboplatin (IT) followed by concurrent Paclitaxel, Carboplatin and Radiotherapy (CRT) in Advanced Head and Neck Squamous Cell Cancers (HN-SCC)" at American Society of Clinical Oncology Meeting, Orlando Florida

Committee:
• Chairman, Thoracic Committee, Brown University Oncology Group

Society: Member, Executive Committee, New England Cancer Society

Alan Rosmarin, M.D.
Invited presentations:
• "Myelodysplastic Syndromes: Contemporary Management and Novel Approaches" at Beth Israel Deaconess Medical Center, Boston, MA
• "CML: A Model Disease for Targeted Therapy" at Rhode Island Hospital Grand Rounds, Providence, RI
• "Current Approaches and Future Trends in Cancer Therapy" at Brown University Oncology Group (BrUOG) Seminar, Edgartown, MA
• "Myelodysplastic Syndromes: Contemporary Management and Novel Approaches" at Boston University Medical Center, Boston, MA
• "Workshop on Myeloid Development" at Annual Myeloid and Stem Cell Workshop, Philadelphia, PA
• "GABP (GA Binding Protein), Sp1 and p300 Physically and Functionally Interact to Regulate Myeloid Transcription of CD18 in Response to
Retinoic Acid” at Fifth International Meeting on Myeloid Stem Cell Development and Leukemia, Annapolis, Maryland.

- “GA Binding Protein (GABP) in the Regulation of Myeloid Gene Expression and Differentiation” at Chicago Department of Biochemistry and Molecular Biology at University of Illinois, Chicago, IL

Howard Safran, M.D.
Invited presentations:
- “Neoadjuvant Herceptin, Paclitaxel and Cisplatin and Radiation for Adenocarcinoma of the Esophagus” at the Eighth International Conference on Gastrointestinal Malignancies, Washington, D.C.
- “A phase II trial of Herceptin and Gemcitabine for Metastatic Pancreatic Cancers that Overexpress HER-2/neu” at ECCO in Lisbon, Portugal

Fred Schiffman, M.D.
- “Top Doc” – Rhode Island Monthly Magazine

William Sikov, M.D.
Invited presentations:
- “Multicenter, 3-arm randomized study of high-dose weekly paclitaxel versus standard-dose weekly paclitaxel for metastatic breast cancer” at American Society of Clinical Oncology (ASCO) annual meeting, Orlando, FL
- “Cancer Clinical Trials and Older Patients” at Combined Oncology/Geriatrics Symposium, Providence, RI
- “The Changing Face of Hormonal Therapy” at Oncology Grand Rounds, Dartmouth Hitchcock Medical Center, Hanover, NH

Gary Strauss, M.D., MPH
Invited presentations:
- “Island-Lake Model and Cancer: Implications for Randomization Failure in Randomized Population Trials” at Working Group in Quantitative Methods in Cancer: Harvard School of Public Health, Boston, MA
- “Should We Be Screening for Cancer?” at National Council of Jewish Women, Providence, RI
- “Cancer Screening is Effective and Cost-Effective: Pro” at American Association of Thoracic Surgery, Boston, MA
- “Smoking-related Adenocarcinoma of the Lung: Now the Most Common Cause of Cancer Death in the United States” at American Society of Clinical Oncology Annual Meeting, Chicago, IL

Rochelle Strenger, M.D.
- Co-recipient of the Rhode Island Medical Women’s Association’s “Woman Physician of the Year Award for 2001”

Nancy Thompson, PhD
Invited presentations:
- “Oncofetal and Amino Acid-Responsive hepatic LAT1/CD98 Expression” at International Society of Differentiation Meeting, Lyon, France
- “Mentoring and Minority Recruiting in Pathobiology” at American Society for Investigative Pathology Graduate Program Director’s Workshop, San Diego, CA

Edward Wittels, M.D.
- Elected to faculty of the Alpha Omega Alpha Honor Medical Society, Brown Medical School
# HEMATOLOGY/ONCOLOGY FELLOWSHIP PROGRAM

## GRADUATES 2002

<table>
<thead>
<tr>
<th>Fellow</th>
<th>Medical School</th>
<th>Residency Program</th>
<th>Post-fellowship Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vanessa Johnson, M.D.</td>
<td>Cornell University Medical College, New York, NY</td>
<td>Brown General Internal Medicine, Rhode Island Hospital, Providence, RI</td>
<td>National Cancer Institute Post-doctoral R25 Training Grant, Providence, RI</td>
</tr>
<tr>
<td>Ahmed Nadeem, M.D.</td>
<td>King Edward Medical College, Lahore, Pakistan</td>
<td>Yale University, Bridgeport Hospital, Bridgeport, CT</td>
<td>Full-time Staff, Memorial Hospital of Rhode Island, Pawtucket, RI</td>
</tr>
<tr>
<td>Nadia Ramdin, M.D.</td>
<td>UMDNJ – Robert Wood Johnson School of Medicine, NJ</td>
<td>Boston University, Roger Williams Medical Center, Providence, RI</td>
<td>Private practice of Hematology/Oncology, Ft. Lauderdale, FL</td>
</tr>
</tbody>
</table>

## GRADUATES 2003

<table>
<thead>
<tr>
<th>Fellow</th>
<th>Medical School</th>
<th>Residency Program</th>
<th>Post-fellowship Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maria Constantinou, M.D.</td>
<td>Ross University Portsmouth, Dominica</td>
<td>Yale University, Norwalk Hospital, Norwalk, CT</td>
<td>Private practice with Vincent Armenio, M.D., East Providence, RI</td>
</tr>
<tr>
<td>Wojciech Dolata, M.D.</td>
<td>Academy of Medicine, Poznan, Poland</td>
<td>Michigan State University, McLaren Regional Medical Center, Flint, MI</td>
<td>Practice in Canada</td>
</tr>
<tr>
<td>Humera Khurshid, M.D.</td>
<td>Aga Khan University Medical College, Karachi, Pakistan</td>
<td>University of Connecticut, John Dempsey Hospital, Farmington, CT</td>
<td>Private practice, University Medical Group, Warwick, RI</td>
</tr>
</tbody>
</table>

## 2001-2003

<table>
<thead>
<tr>
<th>Fellow</th>
<th>Medical School</th>
<th>Residency Program</th>
</tr>
</thead>
<tbody>
<tr>
<td>Debra Holik, M.D.</td>
<td>New York Medical College, Valhalla, NY</td>
<td>Brown University – The Miriam &amp; Rhode Island Hospitals, Providence, RI</td>
</tr>
<tr>
<td>Katrina Rolen, M.D.</td>
<td>St. Louis University School of Medicine, St. Louis, MO</td>
<td>St. Louis University Health Sciences Center, St. Louis, MO</td>
</tr>
<tr>
<td>Amanda Sun, M.D., Ph.D.</td>
<td>Sun Yat-sen University of Medical Sciences, Guangzhou, P.R.China</td>
<td>Yale University, Norwalk Hospital, Norwalk, CT</td>
</tr>
<tr>
<td>James Tsai, M.D.</td>
<td>St. George's University, St. George's, Granada</td>
<td>UMDNY – New Jersey Medical School, Newark, NJ</td>
</tr>
<tr>
<td>George Zahrah, M.D.</td>
<td>University of Ancona, Ancona, Italy</td>
<td>Yale University, Danbury Hospital, Danbury, CT</td>
</tr>
</tbody>
</table>

## 2002-2003

<table>
<thead>
<tr>
<th>Fellow</th>
<th>Medical School</th>
<th>Residency Program</th>
</tr>
</thead>
<tbody>
<tr>
<td>Douglas Brandoff, M.D.</td>
<td>Mt. Sinai School of Medicine, New York, NY</td>
<td>Lahey Clinic, Burlington, VT</td>
</tr>
<tr>
<td>Bharti Chauhan, M.D.</td>
<td>Pandit JMJ Medical College, Raipur, India</td>
<td>Brown University, Memorial Hospital of RI, Pawtucket, RI</td>
</tr>
<tr>
<td>Samir Desai, M.D.</td>
<td>Northeastern Ohio Universities of Medicine, Rootstown, OH</td>
<td>Summa Health System, Akron, OH</td>
</tr>
<tr>
<td>Ronald Harris, M.D.</td>
<td>Lake Erie College of Osteopathic Medicine, Erie, PA</td>
<td>Temple University, Conemaugh Valley Memorial Hospital, Johnstown, PA</td>
</tr>
<tr>
<td>Linda McMorrow-Ries, M.D.</td>
<td>University of Vermont, Burlington, VT</td>
<td>Brown University, Rhode Island Hospital, Providence, RI</td>
</tr>
</tbody>
</table>
Research and Other Scholarly Activities

FACULTY MEMBERS OF STUDY SECTIONS AND ADVISORY COMMITTEES

Loren Fast, PhD
• Member, ZRG H10 study section at NIH

Douglas Hixson, PhD
• Member, NIEHS study section, Review of Toxico-Genomics Consortium Member Applications

Neal Ready, M.D., PhD
• Study section: Chair, Cancer and Leukemia Group B Protocol #30106: “ZD-1839 (NSC# 715055) with Induction Paclitaxel and Carboplatin followed by either Radiation or Concomitant Radiation with Weekly Paclitaxel and Carboplatin in Stage III Non-small Cell Lung Cancer, a Phase II Study”

Alan Rosmarin, M.D.
• Chairman, American Society of Hematology Simultaneous Session “Regulation of Transcription in Hematopoiesis” at annual meeting, Orlando, FL
• Member, Myeloid Subcommittee, American Society of Hematology
• Chairman, American Cancer Society Leukemia, Immunology, and Blood Cell Development
• Member, National Cancer institute Subcommittee C

Howard Safran, M.D.
• Member, Gastrointestinal Oncology Committee, Radiation Therapy Oncology Group (RTOG)
• Ad Hoc Member, Study Section, “Rapid Access to Intervention Development;” Medical Oncology Chairman, RTOG national protocol, “A Phase II Trial of External Irradiation and Weekly Paclitaxel for Non-Metastatic Unresectable Pancreatic Cancer”
• Medical Oncology Chairman, RTOG/Intergroup national protocol, “A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma”
• Medical Oncology Chairman, RTOG national protocol, “Phase II Study of Paclitaxel, Gemcitabine and Radiation Followed by the Farnesl Transferase Inhibitor R115777 for Locally Advanced Pancreatic Cancer”
• Medical Oncology Liaison to Translation Research Program, RTOG
• Medical Oncology Chairman for upcoming RTOG protocol testing a ras peptide vaccine with chemotherapy as adjuvant therapy for pancreatic cancer

Anthony Mega, M.D.
• Chairman, Genitourinary Subcommittee, Brown University Oncology Group
• Member, Scientific Review Board, Brown University Oncology Group

Fred Schiffman, M.D.
• Co-Chairperson, Committee on Clinical Appointments and Promotions, Brown University Department of Medicine
• Chairperson, Chiefs of Medicine of Federation of Jewish Philanthropies Hospitals
• Governor, American College of Physicians/American Society of Internal Medicine

Nancy Thompson, PhD
• Chair, American Society of Investigative Pathology (ASIP) Committee on Career Development, Women and Minorities; Member, ASIP Council
• Chair, Federation of American Societies of Experimental Biology (FASEB) Excellence in Science Award Committee
• ASIP Delegate to AXXS 2002 Meeting in Washington, D.C., sponsored by Office of Research in Women’s Health
• Co-chair and organizer, American Society for Investigative Pathology Career Development Workshop: “Playing to Win: Elements of Success” in San Diego, CA

TEACHING ACTIVITIES

EDUCATION HONORS

Anthony, Mega, M.D.
• Dean’s Teaching Excellence Award, BioMed 281: Pathophysiology – Hematology, Brown Medical School
• Preceptorship Award – Brown Medical School, Rhode Island Hospital, The Miriam Hospital
• “Teacher of the Year 2001-2002” – Brown Medical School, Hematology/Oncology Fellowship Program

Fred Schiffman, M.D.
• Senior Class Award from Brown University Medical School Class of 2001 in recognition of support and dedication to teaching
• Brown University Dean’s Teaching Excellence Award-2002

Edward Wittels, M.D.
• Dean’s Teaching Excellence Award, BioMed 281: Pathophysiology – Hematology, Brown Medical School
PUBLICATIONS

James Butera, M.D.

Loren Fast, Ph.D.

Mary Anne Fenton, M.D.

Douglas Hixson, Ph.D.

Anthony Mega, M.D.

Alan Rosmarin, M.D.
- Gupta AK, Zibello T, Simkevich CP, Rosmarin AG, Berliner N. Sp1 and C/EBP are necessary to activate the lactoferrin gene promoter during myeloid differentiation. *Blood* 2000; 95:3734-41.
- Bush TS, St. Coeur M, Resendes KK, Rosmarin AG. GA binding protein (GABP) and Sp1 are required, along with retinoid receptors to mediate retinoic acid responsiveness of CD18 (2 Leukocyte Integrin): a novel mechanism of transcriptional regulation in myeloid cells. *Blood* 2003; 101:311-7.

Howard Safran, M.D.
Fred Schiffman, M.D.

William Sikov, M.D.

Rochelle Strenger, M.D.

Nancy Thompson, Ph.D.

Edward Wittels, M.D.
BASIC RESEARCH

Deborah Britt, Ph.D.
- Examination of a Novel Protein, LYRIC, and Its Involvement in Prostate Tumor Suppression Mediated by the Cell Adhesion Molecule (CEACAM1-L), Department of Defense
- The Role of a Novel Protein, LYRIC in Development of Hepatocellular Carcinoma, Lifespan (COBRE Pilot Project)

Loren Fast, Ph.D.
- The Effect of INACTINE on Lymphocyte Response, V. I. Technologies, Incorporated (VITEX)
- Immunological Consequences of Transfusion, NIH/National Heart Lung & Blood Institute
- Induction of Anti-Tumor Immunity Using CD4+ T Cells as Antigen-Presenting Cells, Rhode Island Cancer Council, Incorporated

Douglas Hixson, Ph.D.
- COBRE-The Role of Mitochondrial Uncoupling Protein-2 (UCP2) in Colon Carcinogenesis, NIH/National Center for Research Resources
- Center for Cancer Research Development (COBRE) Proteomics, NIH/National Center for Research Resources
- Center for Cancer Research Development (COBRE) Administrative, NIH/National Center for Research Resources
- Molecular Determinants of Multicellular Organization, NIH/National Cancer Institute
- Cellular Origins of Liver CancerGenesis of Liver Carcinomas With Oval Cell Traits, NIH/National Cancer Institute
- FACTOR VIII12th International CEA Symposium, Octapharma Pharmaceutical, NIH/National Cancer Institute

Yow-Pin Lim, M.D., Ph.D.
- Therapeutic and Prognostic Application of Human Plasma Inter/alpha Inhibitor in the Management of Sepsis, The Slater Center for Biomedical Technology
- Immunoregulatory Role of Granzyme in Sepsis, Lifespan

Andrew Makarovski, Ph.D.
- Effect of Taxotere/Estramustine on the Phenotype of Aggressive Prostate Cancer Cell, Aventis Pharmaceuticals Products, Incorporated

Alan Rosmarin, M.D.
- Center for Genetics and Genomics, NIH/National Institutes of Health/Brown

Nancy Thompson, Ph.D.
- Director, Pathobiology Graduate Program, Brown University
- Amino Acid Regulated Gene Expression in Tumorigenesis, American Institute for Cancer Research
- Expression & Role of TA1, Oncofetal Gene in Liver Cancer, NIH/National Cancer Institute

CLINICAL RESEARCH

James Butera, M.D.
- Phase II Study of ST1571 vs Interferon-a Combined with Cytarabine in Patients with Newly Diagnosed Cancer, Novartis Pharmaceuticals Corporation

Anita Kestin, M.D.
- Prevent Study, Brigham & Women’s Hospital

Louis Leone, M.D.
- Cancer and Leukemia Group B Foundation, Cancer and Leukemia Group B Foundation

Anthony Mega, M.D.
- BrUOG NHL-83(Amgen) A Phase I Study of Escalating Doses of Gemcitabine Combined with Standard CHOP Chemotherapy with G-CSF Support (G-CHOP-G) in Patients with Intermediate/high Grade or Mantle Cell NHL, Amgen
- LS-P-RE-107 Interleukin-2 in an Alternative Dose (The ILIAD Trial) Treatment of Patients with Metastatic Renal Cell Carcinoma with Low-Dose Proleukin, Chirion
• BrUOG Pros-90 A Phase I/II Study of Taxol, Carboplatin and Colchicine (TCC) in Androgen Independent Prostate Cancer, Bristol Myers Squibb
• BrUOG NHL-83(Eli Lilly) A Phase I Study of Escalating Doses of Gemcitabine Combined with Standard CHOP Chemotherapy with G-CSF Support (G-CHOP-G) in Patients with Intermediate/high Grade or Mantle Cell NHL
• A Randomized, Multicenter, Phase II Evaluation of Ontak in Patients with Previously Treated, Indolent, B-Cell, Non-Hodgkin’s Lymphoma, Ligand

Neal Ready, M.D.
• Comparison of Strontium and Samarium Uptake and Retention in a Murine Model for Bone Metastasis, Amersham Corporation
• A Phase I Multicenter Study of Continuous Oral Administration of SCH 66336 and IV Paclitaxel in Pati, Schering-Plough Research Institute
• A Phase III Randomized Trial of Active Immunotherapy with a Polyvalent Melanoma Vaccine (C-VAX) Versus Biotherapy with Interferon x-2b as a Post-Surgical Treatment for Stage III Melanoma, Brown University
• A Phase III Randomized Double Blind Trial of Immunotherapy with Polyvalent Melanoma Vaccine (C-VAX) Plus BCG vs Placebo Plus BCG as a Post Surgical Treatment for Stage IV Melanoma, Brown University
• BRUOG PA-77 Herceptin and Gemcitabine for Metastatic Pancreatic Cancer That Overexpresses HER-2NEU, Brown University
• BrUOG PA-A-128 A Phase III Double Blind Placebo Controlled Trial of Gemcitabine Plus Placebo Versus Gemcitabine Plus R115777 in Patients With Advanced Pancreatic Cancer, Brown University
• BRUOG ESO-78 A Phase I/II Trial of Herceptin, Paclitaxel, Cisplatin and Radiation Followed by Maintenance Herceptin for Adenocarcinomas of the Esophagus, Brown University
• A Randomized Double Blind Phase III Comparative Trial of 2 Doses of ZD1839 (IRESSA) In Combination W, Covance, Incorporated
• Sunbelt Melanoma Trial: A Multicenter Trial of Adjuvant Interferon Alfa-2B for Melanoma Patients with Early Lymph Node Metastasis Detected by Lymphatic Mapping and Sentinel Lymph Node Biopsy, Schering-Plough Corporation
• A Two Part Multiple Dose Clinical Trial of Safety and Efficacy of ABX-EGF in Combination with Paclitaxel and Carboplatin in Patients with Advanced Non-Small Cell Lung Cancer (LS-P-LU-303), Amgen, Incorporated

Alan Rosmarin, M.D.
• BrUOG MDS-85 Phase I/II Study of ONTAK in the Treatment of Myelodysplastic Syndromes, Brown University
• An Open-label, Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy with Darbepoetin also (NESP), Amgen

• A Phase I/II Study of Estramustine, Docetaxel and Ifosfamide with Carboplatin in recurrent or Metastatic Head and Neck Squamous Cell Cancers (HN-SCC), Aventis Pharmaceuticals Products, Incorporated
• A Phase 3 Randomized Study of Lonafarbin in Combination with Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients with Non-Small Cell Lung Cancer, Schering-Plough Corporation
• Sigma-Tau-ST 01-401 Phase I Study of Oral St 1481 Administered Once Weekly Every 3 Out of 4 Weeks in Patients With Advanced Solid Malignancies, Sigma-Tau Pharmaceuticals Incorporated
• BrUOG H & N 86 Induction Chemotherapy with Weekly Taxol, Ifosfamide, and Carboplatin Followed by Concurrent Weekly Taxol and Carboplatin and Radiotherapy in Locally Advanced Head and Neck Cancers, Bristol-Myers Squibb, Incorporated
• A Phase III Randomized Trial of Active Immunotherapy with a Polyvalent Melanoma Vaccine (C-VAX) Versus Biotherapy with Interferon x-2b as a Post-Surgical Treatment for Stage III Melanoma, Brown University/NCI/John Wayne Cancer Institute
• Phase II Study of Weekly Gemcitabine and Paclitaxel for Advanced Non-Small Cell Carcinoma of the Lung (Eli Lilly & Co), Eli Lilly and Company
• Outpatient Concurrent Chemo-Biotherapy for Metastatic Malignant Melanoma Phase II, Chiron Corporation
• Outpatient Concurrent Chemo-Biotherapy for Metastatic Malignant Melanoma, Phase II, Schering Corporation
• The SILVA Study: Survival in International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study with Adjuvant BEC2 and BCG, Imclone Systems Incorporated
• A Multicenter, Open Label Randomized Study of Three Schedules of Weekly Taxol Induction Therapy Followed by Weekly Taxol Maintenance Therapy in Metastatic Breast Cancer Patients, Theradex
Howard Safran, M.D.

- BrUOG ESO-78 A Phase I/II Trial of Herceptin, Paclitaxel, Cisplatin and Radiation Followed by Maintenance Herceptin for Adenocarcinomas of the Esophagus, Genentech Inc./Brown University
- LS-P-PA103 Randomized Phase II Trial to Evaluate the Effect of Gemcitabine Plus R115777 Versus Gemcitabine Plus Placebo on Time to Deterioration in Patients with Advanced Pancreatic Cancer (R115777-INT-16), PRA/Janssen
- BrUOG PA-77 Herceptin and Gemcitabine for Metastatic Pancreatic Cancers that Overexpress HER-2/neu, Brown University
- BrUOG LU-A-117 The Silva Study-Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study with Adjuvant BEC2 and BCG (EORTC Protocol 08971), Brown University
- BrUOG LU-A-109 A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Marimastat in Patients with Minimal Disease Stage III Non-Small Cell Lung Cancer (CO3/IVB/173), Brown University
- BrUOG PA-77 Phase II Study of Herceptin and Gemcitabine For Metastatic Pancreatic Cancers That Overexpress HER-2/Neu, Lilly Research/Brown University
- BrUOG PA-A-128 Phase III, Double-Blind, Placebo Controlled Trial of Gemcitabine vs. R115777 Plus Gemcitabine in Patients With Advanced Pancreatic Cancer, Janssen Pharm./Brown University
- Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress Her2/NEU (Genentech), Genentech, Incorporated
- R115777-INT-11, A Phase III, Double-blind, Placebo-Controlled Trial of Gemcitabine Plus Placebo Versus Gemcitabine Plus Placebo versus Gemcitabine plus R115777 in Subjects with Advanced Pancreatic Cancer, Janssen
- LS-P-GA010 “A Phase II Study of Epothilone Analog BMS-247550 in patients with Metastatic Gastric Adenocarcinoma Previously Treated with a Taxane, Bristol Myers Squibb
- LS-P-PA109 A Randomized, Open-Label, Multi-center Phase III Study Comparing the Efficacy and Safety of a Combination of Intravenous DX-8951F (exatecan mesylate) plus Gemcitabine to Gemcitabine Alone in Patients with Locally Advanced or Metastatic Cancer, Daiidhi Pharmaceutical Products, Incorporated
- Phase I/II Study of Capecitabine/Taxotere and Carboplatin in Metastatic Adenocarcinoma of the Esophagus and Stomach, Aventis Pharmaceuticals Products, Incorporated
- Percutaneous Radiofrequency Ablation of Bone Metastasis Using CT Guidance, Radionics Instruments/Brown University
- Radiation Therapy Oncology Group (RTOG), NIH/Brown University
- A Phase II Study to Determine the Antitumor Activity of Farnesyltransferase Inhibitor R115777 in Subjects with Relapse Small Cell Lung Cancer, Janssen Pharmaceuticals/Brown University
- A Double-blind, Placebo Controlled, Minimized Phase III Study Comparing Marimastat to Placebo as Adjuvant Therpay in Patients with Respectable Pancreatic Cancer, Brown University
- Phase II Study of TLC D-99 for Hepatobiliary Carcinomas, Liposome/Brown University
- A Compassionate Use Study of Oxaliplatin for Previously Treated Colorectal Cancer Patients, Jansenn Pharmaceuticals/Brown University
- A Phase I Trial of Tarceva, Gemcitabine, Paclitaxel, and Radiation for Locally Advanced Pancreatic Cancer, Genentech, Incorporated
- An Open-Label, Phase I Study to Evaluate the Safety and Tolerability of rV-CEA(6d)/Tricom Admixed With rV-MUC-1 followed by rV-CEA(6D)/Tricom in Combination With GM-CSF in Subjects with Unresectable Adenocarcinoma of the Pancreas, Therion Pharmaceuticals
- Safety and Efficacy of Oral Gimatecan (ST 1481) Administered on a dx5 Schedule Every 28 Days as Second Line Therapy for Metastatic Colorectal Cancer in Patients without Previous Exposure to Camptothecins (A Phase II Trial), Sigma-Tau Pharmaceuticals Incorporated

William Sikov, M.D.

- Cancer and Leukemia Group B, NIH/National Cancer Institute,
- CALGB Foundation Grant, NIH/National Institutes of Health/University of Chicago
- A Phase II Study of Weekly Gemcitabine and Paclitaxel for Advanced NSCL, Brown University
- A Phase II Study of Gemcitabine Supplementation in Patients Receiving Weekly Taxol for Metastatic Breast on Non-Small Cell Lung Carcinomas, Bristol-Myers Squibb/BU
- A Randomized Multicenter, Phase II Study of Bolus/Infusion 5FU/LV vs Oxaliplatin and Bolus Infusion 5-FU/LV as Third-Line Treatment of Patients with Metastatic Colorectal Carcinoma EFC 4760, Prologue Research
- BMS CA 163-012-010 A Phase II Study of Epothilone analog BMS-247550 in Patients with Metastatic Colorectal Cancer Previously Treated with a Fluorpyrimidie and Irinotecan, Bristol Myers Squibb
• A Multicenter, Open-label, Randomized, Two-arm Study of Irinotecan (CPT-11) versus the combination of Oxaliplatin and Irinotecan (CPT-11) as Second Line Treatment of Metastatic Colorectal Carcinoma, Sanofi-Synthelabo
• Gemcitabine and Capectibine in Advanced Breast Cancer: A BrUOG Phase II Study, Roche Laboratories
• A Randomized, Open Label, Multicenter Study of Primary Prophylaxis with Neulasta Versus Secondary Prophylaxis as and Adjunct to Chemotherapy in Elderly Subjects with Cancer, Amgen, Incorporated
• Phase I Study of Weekly Docetaxel and Doxorubicin in Advanced Cancers, Brown University
• Phase I Study of Weekly Docetaxel and Liposomal Doxorubicin HCl (Doxil) in Advanced Cancers, Brown University
• An Open-Label, Multicenter, Randomized, Phase III comparator Study of Oral Topotecan Versus Intravenous Topotecan for Second-Line Therapy in Patients with SCLC Who Have Relapsed Greater than or equal to 90 Days After Completion of First Line Therapy, SmithKline Beecham/Brown University
• Multicenter Phase II Study of Herceptin and Navelbine as First-Line Therapy for HER2-positive. Metastatic Breast Cancer, Dana Farber/GLAXO
• Gemcitabine and Capectibine in Advanced Breast Cancer: A BrUOG Phase II Study, Lilly Research/ Brown University

Rochelle Strenger, M.D.
• NSABP Breast Cancer Prevention Trial, NIH/ National Institutes of Health/Dana Farber Cancer Inst.